Why the FDA Won't Approve Peptides or NAD+ — And What That Actually Tells You

Here's a question worth sitting with: if peptides and NAD+ are so effective — and the research supporting them is so compelling — why hasn't the FDA approved them?

It's a fair question. And the honest answer is one the pharmaceutical industry would rather you not think too hard about.

The FDA Doesn't Approve Things. It Approves Applications.

This is the part most people miss. The FDA doesn't go out and evaluate every compound that might benefit human health. It responds to applications — and applications cost money. Serious money. A full clinical trial package to support a new drug application runs somewhere between $1 billion and $2.6 billion on average, according to research published in the Journal of Health Economics. That investment only makes sense if the company funding it can recoup the cost through exclusive sales rights.

Exclusive sales rights come from patents.

And here's the problem: you cannot patent a naturally occurring molecule.

You Can't Own What Nature Already Made

In 2013, the Supreme Court ruled in *Association for Molecular Pathology v. Myriad Genetics* that naturally occurring DNA sequences cannot be patented. The same principle applies broadly across biochemistry. If a molecule exists in nature — if your body already makes it — a pharmaceutical company cannot claim exclusive ownership of it.

Peptides are short chains of amino acids. Your body produces thousands of them. BPC-157 is derived from a protein found in gastric juice. TB-500 is a synthetic version of a peptide your body already synthesizes called Thymosin Beta-4. Ipamorelin mimics the action of ghrelin, a hormone your stomach secretes every time you're hungry. NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every single cell in your body — it's as fundamental to human biology as ATP.

None of these can be patented in their natural form.

So no pharmaceutical company will spend $2 billion running the clinical trials needed to get FDA approval, because even if they succeed, any competitor can immediately manufacture and sell the same molecule. There's no return on that investment. The system isn't broken — it's working exactly as designed. It just wasn't designed with your health as the primary variable.

The Irony of "Unapproved"

When something is labeled "not FDA approved," most people hear "unsafe" or "unproven." That's a conflation the pharmaceutical industry benefits from enormously.

FDA approval is a regulatory status, not a scientific verdict. It means a company has submitted a complete application and the FDA has reviewed it. The absence of that approval tells you nothing about whether a compound works or whether it's safe. It tells you whether a company found it profitable to apply.

Consider: aspirin was used therapeutically for decades before the modern FDA approval process existed. Vitamin D, magnesium, omega-3 fatty acids — none of these are FDA-approved drugs, yet the evidence base for their health effects is enormous. NAD+ precursors like NMN and NR are sold openly as supplements with substantial peer-reviewed research behind them. The FDA's position on these compounds isn't a scientific judgment. It's a regulatory gap created by economics.

What the Research Actually Shows

The absence of FDA approval has not stopped researchers from studying these compounds. The literature on peptides and NAD+ is substantial and growing.

BPC-157 has been studied in over 100 peer-reviewed papers, primarily in animal models, showing accelerated healing of tendons, ligaments, muscle tissue, and gut lining. The compound appears to work by upregulating growth hormone receptors and promoting angiogenesis — the formation of new blood vessels — in damaged tissue. The reason there are no large human trials isn't because the results are unconvincing. It's because no one will fund them.

NAD+ research has attracted more mainstream attention, partly because it sits at the intersection of aging science and metabolic health. Studies from Harvard, MIT, and Washington University have demonstrated that declining NAD+ levels correlate with virtually every hallmark of aging: mitochondrial dysfunction, DNA damage accumulation, impaired cellular repair, and metabolic slowdown. Research by Dr. David Sinclair at Harvard has shown that restoring NAD+ levels in aging mice reverses measurable markers of cellular aging. Human trials on NAD+ precursors have shown improvements in muscle function, insulin sensitivity, and cognitive performance.

The research isn't fringe. It's published in Cell, Nature, and the New England Journal of Medicine. The gap isn't in the science. It's in the economics.

The 503A Compounding Pharmacy System

So how do people actually access these compounds? In the United States, peptides and NAD+ are available through a legal framework called 503A compounding pharmacies. These are licensed pharmacies that prepare customized medications for individual patients, typically under the supervision of a licensed healthcare provider.

This is the same system that allows a pharmacist to prepare a medication in a specific dose or formulation not commercially available — a practice that has existed in American medicine for over a century. Compounded peptides are not black-market products. They're prepared in licensed facilities, subject to state pharmacy board oversight, and dispensed through legitimate medical channels.

The FDA has taken an increasingly aggressive posture toward compounded peptides in recent years, particularly after removing BPC-157, TB-500, and several others from the list of permissible bulk drug substances in 2023. The stated rationale was that these compounds hadn't been proven safe and effective through the standard approval process. The unstated reality is that the standard approval process was never designed for compounds that can't be patented.

The Deeper Question

There's a more uncomfortable question underneath all of this, and it's worth asking directly: whose interests does the current system serve?

The FDA was created to protect consumers from dangerous and fraudulent products — a genuinely important function. But the approval pathway it administers was built around a pharmaceutical industry model that requires patent exclusivity to justify R&D investment. That model works well for synthetic drugs with novel mechanisms. It works poorly for naturally occurring compounds, repurposed generics, and anything else where the profit motive doesn't align with the research need.

The result is a system where a synthetic GLP-1 agonist like semaglutide (Ozempic) gets a billion-dollar clinical trial because Novo Nordisk can patent the specific molecular modification that makes it work. Meanwhile, the naturally occurring GLP-1 peptide your intestines already produce — which has the same basic mechanism — gets no trial, no approval, and no insurance coverage, because there's no one to fund the application.

This isn't a conspiracy. It's an incentive structure. And once you understand it, the phrase "not FDA approved" starts to mean something very different.

What This Means for You

None of this means you should take every peptide or supplement that claims benefits. The research quality varies significantly across compounds. Some peptides have robust animal data but limited human trials. Others have been studied extensively in humans. NAD+ has one of the stronger evidence bases in the longevity space. BPC-157 has compelling animal data but limited controlled human research. Semaglutide and tirzepatide, notably, are FDA-approved — because the pharmaceutical companies that developed them could patent their specific formulations.

The right approach is the same one that applies to any health decision: look at the actual research, understand the mechanism, consider the risk profile, and work with someone who knows the literature. Not because the FDA's absence of approval is irrelevant — it does matter — but because it's not the whole story.

The whole story is that the compounds your body already makes are, almost by definition, the ones the current approval system is least equipped to evaluate. That's worth knowing.

Body Techs Wellness & Esthetics provides educational resources on peptides and NAD+ for research and informational purposes only. All content on this page is for educational reference and does not constitute medical advice. Consult a licensed healthcare provider before beginning any wellness protocol.